Clinical Trials | Novartis

Press Release
Aug 30, 2025

Novartis Leqvio® shows statistically significant and clinically meaningful early LDL-C goal achievement with less muscle pain
Press Release
Aug 18, 2025

New Novartis ESC data highlights strength of cardiovascular portfolio
Press Release
Aug 11, 2025

Novartis announces both ianalumab Phase III clinical trials met primary endpoint in patients with Sjögren’s disease
Press Release
Feb 28, 2025

Novartis data presentations at AAAAI and AAD underscore commitment to advancing treatment of hidradenitis suppurativa (HS) and chronic spontaneous urticaria (CSU)
Press Release
Aug 28, 2024

Novartis twice-yearly* Leqvio® demonstrated clinically meaningful, statistically significant LDL-C lowering as a monotherapy in patients at low or moderate ASCVD risk
Press Release
Apr 23, 2024

Novartis radioligand therapy Lutathera® FDA approved as first medicine specifically for pediatric patients with gastroenteropancreatic neuroendocrine tumors
Story
Feb 14, 2024

Listening to the CML patient community
Story
Dec 12, 2023

Innovation fueled by compassion
Story
Dec 08, 2023

Shoulder to shoulder
Press Release
Nov 20, 2023

Novartis showcases significant data updates from Kisqali®, iptacopan and Scemblix® at SABCS and ASH
Press Release
Oct 07, 2021

Novartis to present broad range of portfolio data at ECTRIMS, reinforcing long-standing commitment to people living with multiple sclerosis
Press Release
Jun 02, 2021

Novartis presents positive Phase III results from JUNIPERA study supporting Cosentyx® as a potential treatment in a JIA population at EULAR 2021